Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico.
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Col. Sección XVI, Tlalpan, 14000, Mexico, CP, Mexico.
Clin Rheumatol. 2020 Jun;39(6):1935-1943. doi: 10.1007/s10067-020-04936-5. Epub 2020 Jan 22.
To validate the renal risk score in a cohort of patients with advanced kidney damage.
A total of 72 patients with biopsy-proven ANCA glomerulonephritis with >12 months of follow-up were studied. The renal risk score was calculated and evaluated by survival analysis for time of renal survival. Cohort-specific clinical, histopathologic, and post-treatment factors associated with renal survival were determined by Cox regression analysis.
Kidney biopsies were classified as focal, crescentic, mixed, and sclerotic classes in 6 (8%), 4 (6%), 25 (35%), and 37 (51%) patients, respectively. The 1-, 3-, and 5-year renal survival rates were 79%, 73%, and 68%, respectively. Patients were segregated by the risk score in low- (18%), medium- (47%), and high-risk (35%) groups. Patients in the low-risk group had 36-, 60-, and 84-month renal survival of 100%; those in the medium risk 85% (95% CI 72-92), 81% (95% CI 66-95), and 76% (95% CI 60-92), respectively; and those in the high risk 37% (95% CI 17-57), 26% (95% CI 7-45), and 18% (95% CI 1-36), respectively. Six (43%) of the 14 patients in the high-risk group recovered renal function after the initial episode, and 2 (14%) remained dialysis-free. Other parameters associated with renal survival included age, proteinuria, general symptoms, cellular crescents, glomerulosclerosis, tubulointerstitial lesions, best post-treatment eGFR, and renal relapses.
We validated the renal risk score as a prognostic tool in a cohort with predominantly mixed and sclerotic histologic categories. Since patients in the high-risk group still benefited from immunosuppressive therapy, this score should be used in conjunction with other predictive parameters to aid therapeutic decisions.Key Points• The ANCA renal risk score is validated in a cohort with advanced kidney damage.• Patients in the high-risk group still benefited from immunosuppressive therapy.• Parameters not included in the risk score are associated with renal survival and may be useful.
在一组晚期肾损伤患者中验证肾风险评分。
研究了 72 例经活检证实的抗中性粒细胞胞浆抗体肾小球肾炎患者,随访时间超过 12 个月。通过生存分析计算并评估肾风险评分,以评估肾生存时间。通过 Cox 回归分析确定与肾生存相关的特定于队列的临床、组织病理学和治疗后因素。
肾脏活检分别分类为局灶性、新月体性、混合性和硬化性,分别为 6 例(8%)、4 例(6%)、25 例(35%)和 37 例(51%)。1、3 和 5 年的肾存活率分别为 79%、73%和 68%。根据风险评分将患者分为低危(18%)、中危(47%)和高危(35%)组。低危组患者的 36、60 和 84 个月的肾存活率分别为 100%;中危组患者分别为 85%(95%CI72-92)、81%(95%CI66-95)和 76%(95%CI60-92);高危组患者分别为 37%(95%CI17-57)、26%(95%CI7-45)和 18%(95%CI1-36)。高危组 14 例患者中有 6 例(43%)在初次发作后恢复了肾功能,2 例(14%)仍未进行透析。与肾生存相关的其他参数包括年龄、蛋白尿、全身症状、细胞性新月体、肾小球硬化、肾小管间质病变、最佳治疗后 eGFR 和肾复发。
我们在一组主要为混合性和硬化性组织学类别的队列中验证了肾风险评分作为一种预后工具。由于高危组患者仍从免疫抑制治疗中获益,因此该评分应与其他预测参数一起使用,以辅助治疗决策。
ANCA 肾风险评分在晚期肾损伤患者的队列中得到验证。
高危组患者仍从免疫抑制治疗中获益。
未包含在风险评分中的参数与肾生存相关,可能有用。